Wegovy VA Coverage Pathway: How Veterans Can Access Semaglutide 2.4 mg

VA Formulary Status for Wegovy

The VA Pharmacy Benefits Management (PBM) program maintains a National Formulary that determines which medications are available without additional authorization at VA medical centers. Semaglutide at the 2.4 mg dose marketed as Wegovy is not currently listed on this formulary, though lower-dose semaglutide (Ozempic 0.5 mg, 1 mg, 2 mg) carries formulary status for type 2 diabetes management [1].

This distinction matters. A veteran with type 2 diabetes may already receive semaglutide through the VA for glycemic control, but the higher 2.4 mg weekly dose approved specifically for chronic weight management requires a separate non-formulary drug request (NFDR). The VA PBM issues clinical guidance documents and criteria for use that local facilities reference when evaluating these requests [2].

Each VA medical center operates its own Pharmacy and Therapeutics (P&T) committee, so approval timelines and specific documentation requirements can differ between facilities. The Veterans Health Administration (VHA) Directive 1108.08 governs the NFDR process nationally, but local interpretation introduces variability [3]. Veterans enrolled in VA healthcare with a primary care provider assigned are eligible to initiate the request process.

The Non-Formulary Drug Request Process

Getting Wegovy approved through the VA follows a structured pathway. The veteran's VA provider submits a non-formulary drug request through the Computerized Patient Record System (CPRS), documenting the clinical rationale and supporting evidence.

Standard criteria for approval include a BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnea [4]. The FDA label for semaglutide 2.4 mg mirrors these thresholds, which are consistent with the 2022 American Gastroenterological Association (AGA) guideline recommendations for pharmacotherapy in obesity [5].

Most VA facilities also require documentation that the veteran has tried and not responded adequately to at least one formulary weight-management option. Current VA formulary agents for obesity may include orlistat and phentermine-topiramate in some facilities. Active participation in the VA MOVE! Weight Management Program, a behavioral lifestyle intervention, is frequently a prerequisite [6].

The request goes to the facility's P&T committee or a designated clinical pharmacist reviewer. Turnaround ranges from a few days to several weeks. If denied, providers can appeal with additional clinical documentation. Veterans should ask their provider to note specific trial data supporting the request. The STEP 1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo [7]. That magnitude of effect exceeds what older formulary agents deliver and strengthens the clinical case.

Why the VA Treats Obesity Pharmacotherapy Differently

Obesity affects a disproportionate share of the veteran population. Data from the Veterans Affairs Healthcare System show that roughly 41% of veterans enrolled in VA care meet criteria for obesity (BMI ≥30), compared with about 42% in the general U.S. adult population per CDC estimates [8]. Among post-9/11 veterans, rates trend higher still.

The VA MOVE! program, established in 2006, remains the largest healthcare system-based weight management program in the United States and has served over 1.5 million veterans [9]. It provides dietary counseling, physical activity support, and behavioral health coaching. However, a 2020 analysis published in Obesity found that MOVE! participants achieved a mean weight loss of approximately 2.2 kg at 12 months [10]. That figure falls well below the 5% body weight threshold that clinical guidelines define as "clinically meaningful."

This gap between behavioral intervention alone and the outcomes now achievable with GLP-1 receptor agonists has prompted ongoing policy discussions within the VHA. The SELECT trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease, independent of diabetes status [11]. For a veteran population with elevated cardiovascular risk, that finding carries significant weight in formulary decisions.

Dr. Donna Ryan, former president of the Obesity Society, has stated: "The SELECT results change the clinical calculus. We now have a weight-management drug with proven cardiovascular benefit, which puts it in the same evidence class as statins for secondary prevention" [11].

Cost Breakdown: Cash, Insurance, and VA Copays

The financial picture varies substantially depending on how a veteran accesses Wegovy.

VA pharmacy copay. If approved through the NFDR, veterans receive Wegovy at the standard VA outpatient prescription copay. For most veterans, this falls between $5 and $11 per 30-day supply, depending on their VA priority group and whether the medication is classified as preferred or non-preferred [12]. Veterans with service-connected disabilities rated at 50% or higher pay no copays. This makes VA coverage, when approved, one of the most affordable pathways available.

Cash price without insurance. At retail pharmacies, Wegovy carries a wholesale acquisition cost (WAC) of approximately $1,349 per month. Actual cash prices at chain pharmacies may range from $1,300 to $1,600 depending on the dose and location [13].

Commercial insurance. Coverage through private plans remains inconsistent. A 2024 KFF analysis found that roughly one in four large-employer health plans covered GLP-1 receptor agonists for obesity as of mid-2024, though that share has been increasing [14]. For veterans with dual coverage (VA plus a private plan through an employer or spouse), exploring the commercial insurance pathway simultaneously may be worthwhile.

Medicare Part D. Federal legislation signed in 2024 began a phased process for potential Medicare Part D coverage of anti-obesity medications. As of early 2026, implementation details remain subject to CMS rulemaking and plan-level formulary decisions [15]. Veterans enrolled in both VA and Medicare should check current Part D formulary status with their plan.

Novo Nordisk Savings Programs

Novo Nordisk operates the WeGoTogether savings card program, which can reduce out-of-pocket costs for commercially insured patients to as low as $0 for up to a specified period [16]. Eligibility restrictions apply. Federal healthcare beneficiaries, including those using VA, TRICARE, or Medicare coverage, are typically excluded from manufacturer copay cards by federal anti-kickback statute provisions.

However, veterans filling prescriptions through commercial insurance (not the VA pharmacy benefit) may qualify if they meet the program's criteria. The distinction hinges on which payer adjudicates the claim.

Novo Nordisk also supports the Novo Nordisk Patient Assistance Program (PAP) for uninsured patients meeting income thresholds, generally at or below 400% of the federal poverty level [16]. Veterans who are not enrolled in VA healthcare and lack other insurance should explore this option directly.

The Compounded Semaglutide Alternative

Since early 2024, compounded semaglutide has been available through 503A and 503B compounding pharmacies at significantly lower cost, often around $199 per month or less [17]. Compounded versions became available under the FDA drug shortage pathway when brand-name semaglutide products appeared on the FDA shortage list.

As of 2026, the status of compounded semaglutide depends on whether the FDA shortage designation remains active. The FDA has taken enforcement actions and issued guidance regarding the conditions under which compounding of drugs that are copies of approved products is permissible [18]. Veterans considering compounded semaglutide should verify the current shortage status with the FDA and confirm that their source pharmacy holds proper licensure.

The VA pharmacy system itself does not dispense compounded semaglutide. Veterans pursuing this route would obtain it outside the VA system, typically through a telehealth provider or direct-to-patient compounding pharmacy. Quality and dosing standardization are considerations. The FDA has warned about risks associated with compounded semaglutide products, including reports of adverse events linked to products containing salt forms (semaglutide sodium) not present in the FDA-approved product [18].

TRICARE vs. VA: Which Pathway Works Better?

Veterans with TRICARE eligibility (retirees, reservists, and dependents) face a different formulary structure. TRICARE covers Wegovy under its pharmacy benefit with prior authorization, managed through Express Scripts [19]. The TRICARE prior authorization criteria align with FDA labeling: BMI ≥30 or BMI ≥27 with comorbidity, plus documentation of lifestyle modification.

For dual-eligible veterans (VA plus TRICARE), comparing pathways may be practical.

TRICARE copays for Wegovy fall into the specialty tier. Through TRICARE Home Delivery, the copay for a 90-day supply of a non-formulary brand drug is $77 as of the 2026 benefit year. At retail, it runs higher. The VA copay, if the NFDR is approved, remains $5 to $11 per month, making it the less expensive option in most cases [12].

Processing time is the other variable. TRICARE prior authorization decisions are typically returned within 72 hours. VA non-formulary requests can take longer, depending on the facility's review cycle. Veterans who need the medication urgently may find the TRICARE route faster, while those optimizing for cost may prefer VA.

Building a Strong Non-Formulary Request

Veterans can increase the likelihood of NFDR approval by working with their provider to assemble thorough documentation. A well-constructed request typically includes the following elements.

Documented BMI history. Serial weight measurements demonstrating persistent obesity, ideally spanning six months or more, establish chronicity. The 2013 AHA/ACC/TOS guideline for the management of overweight and obesity supports pharmacotherapy when behavioral interventions alone are insufficient [20].

Record of MOVE! participation. VA reviewers look for evidence that the veteran has engaged with the MOVE! program. A minimum of three to six months of documented participation strengthens the case. Attendance records and weight trajectory during the program should be included.

Comorbidity documentation. Listing all weight-related conditions (hypertension, type 2 diabetes, obstructive sleep apnea, osteoarthritis, NAFLD/MASLD) with current treatment regimens demonstrates the clinical burden of obesity. The AACE 2023 consensus statement on obesity recommends a complications-centric approach to obesity management that prioritizes pharmacotherapy for patients with obesity-related complications [21].

Prior medication trials. Documenting trials of formulary agents (with dates, doses, duration, and reason for discontinuation) satisfies the step-therapy requirement.

Cardiovascular risk. For veterans with established cardiovascular disease or multiple risk factors, citing the SELECT trial outcomes directly supports the cardiovascular benefit argument [11]. A 2024 secondary analysis of SELECT found that the cardiovascular benefit was consistent across BMI subgroups, including those with BMI 27 to <30 [22].

What to Do if the Request Is Denied

Denials happen. The most common reasons include incomplete documentation, failure to demonstrate adequate trial of formulary alternatives, or lack of documented MOVE! participation.

First step: ask for the specific denial reason in writing. The VA is required to provide this. Second: address the gap. If the denial cites insufficient lifestyle intervention, enroll in MOVE! and resubmit after three months of participation. If it cites lack of prior pharmacotherapy, discuss a trial of orlistat or another formulary option with your provider.

Veterans also have the right to file a clinical appeal through the VA Patient Advocate at their facility [23]. For systemic concerns about formulary access, contacting the VA PBM directly or reaching out to veterans' service organizations (VSOs) such as the DAV or VFW, which have advocacy staff experienced in healthcare access issues, can be effective.

Congressional representatives' offices also handle VA healthcare casework. A congressional inquiry does not guarantee approval, but it does prompt a formal written response from the facility.

Monitoring and Follow-Up After Starting Wegovy

Once approved, the VA typically requires follow-up documentation to continue the non-formulary authorization. Most facilities set an initial approval period of six to twelve months, after which a renewal request is needed.

Expected benchmarks include achieving at least 5% total body weight loss by 12 to 16 weeks on the maintenance dose (2.4 mg weekly) [4]. The STEP 1 trial showed that responders who achieved ≥5% weight loss by week 20 went on to lose a mean of 18.2% at week 68 [7]. The dose escalation schedule (0.25 mg weekly for 4 weeks, increasing every 4 weeks through 0.5 mg, 1 mg, and 1.7 mg, reaching the 2.4 mg maintenance dose by week 16) should be followed to minimize gastrointestinal side effects.

Labs at baseline and follow-up typically include HbA1c, fasting lipid panel, liver enzymes (ALT, AST), fasting glucose, and a comprehensive metabolic panel. For veterans with pre-existing type 2 diabetes, dose adjustments of sulfonylureas or insulin may be necessary to avoid hypoglycemia. The ADA Standards of Care 2024 recommends reducing sulfonylurea doses by 50% when initiating GLP-1 receptor agonist therapy in patients at hypoglycemia risk [24].

Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) occur in 40 to 50% of patients during dose escalation but typically diminish over weeks. In STEP 1 to 4.5% of participants discontinued due to gastrointestinal adverse events versus 0.8% on placebo [7].